CEO Executive AssistantPharmaceutical product launches are executed by cross-functional teams, not by individual executives. The commercial team, medical affairs, regulatory affairs, supply chain, market access, communications, and legal all have significant roles in a successful launch. When these teams are well-structured, well-delegated, and well-coordinated, launches succeed. When the CEO attempts to coordinate all of these functions personally, launches become executive bottlenecks.
This article addresses the specific delegation challenges of managing a cross-functional pharma launch team: how to structure team authority, how to coordinate without centralizing, and how the CEO can provide strategic direction without becoming an operational manager of the launch process.
The Launch Team Structure
A pharmaceutical launch team is not a traditional functional hierarchy. It is a cross-functional structure organized around the launch objective, with representatives from all relevant functions. Designing this structure effectively is the CEO’s first launch team delegation decision.
The optimal launch team structure has three levels:
Launch Steering Committee (LSC): Senior functional leaders (CCO, CMO, Head of Regulatory, Head of Market Access, Head of Supply Chain) who make cross-functional launch decisions within the CEO-approved launch strategy and investment. Chaired by the CCO. Meets weekly during the launch period.
Launch Working Groups: Functional sub-teams organized by launch track (commercial, medical, regulatory, supply, market access, communications). Each working group has a designated leader and a clear mandate. Working groups resolve issues within their track; cross-track issues go to the LSC.
Launch Program Management Office (PMO): A dedicated program manager or team that coordinates across working groups, manages the launch timeline, facilitates LSC meetings, and produces the launch dashboard. Reports to the CCO or directly to the CEO.
The CEO is not a member of the LSC. The CEO is the executive sponsor who receives LSC progress reports and makes decisions that rise above the LSC’s authority.
Delegating the Launch Planning Process
The launch plan, including the commercial strategy, the launch investment allocation, the key milestones and timelines, and the success metrics, is a document that should be developed by the launch team under CCO leadership and then presented to the CEO for strategic review and approval.
The CEO’s role in launch plan development is input and approval, not development. Early in the planning process, the CEO should communicate the strategic context and constraints: what the organization expects from this launch, what resources are available, what the timeline constraints are, and what market success must look like.
The launch team then develops the plan within this context. The CEO reviews the draft plan, asks strategic questions, identifies any gaps between the plan and the strategic expectations, and approves the final plan. This review should take two to three sessions at most; not the dozens of working sessions that would be required if the CEO were personally developing the plan.
Defining Launch Team Decision Rights
Cross-functional launch teams are vulnerable to decision paralysis when decision rights are unclear. Who decides when the commercial and medical teams disagree on KOL strategy? Who resolves the conflict when regulatory’s preferred label language differs from commercial’s preferred messaging? Who makes the call on supply inventory levels when commercial and finance have different risk tolerances?
These cross-functional decision points need explicit protocols before they arise, not improvised resolution when they do. Define:
- Intra-functional decisions: Each functional lead decides within their domain without escalation
- Cross-functional decisions within the LSC mandate: LSC chair (CCO) has final decision authority after discussion
- Cross-functional decisions with significant financial risk: CFO joins the LSC discussion
- Cross-functional decisions with regulatory compliance implications: CCO (Chief Compliance Officer or Head of Regulatory) has veto authority
- Cross-functional decisions that require resource reallocation above defined threshold: CEO decides
This decision rights framework prevents both paralysis (everything goes to the CEO) and runaway commitments (teams make decisions without appropriate governance).
The CEO’s Relationship with the Launch PMO
The Launch Program Management Office is the operational backbone of the launch team. The launch PMO manages the timeline, tracks milestones, facilitates meeting preparation, and produces the launch dashboard. This is the CEO’s primary intelligence source for launch progress without requiring the CEO to attend operational launch meetings.
Establish a clear protocol for the launch PMO’s reporting to the CEO: a weekly written summary of milestone status, any emerging issues, and any escalations from the LSC. The CEO reviews this summary and responds to any items requiring executive input. The PMO manages all reporting and meeting logistics; the CEO engages only through the defined reporting channel and the periodic executive sponsor reviews.
Managing Launch Team Morale and Culture Without Operational Involvement
A product launch is an intense organizational experience, and the CEO’s role in launch team culture matters even without operational involvement. The CEO who is visible, energizing, and values-affirming with the launch team, without managing their work, provides a form of leadership that no operational involvement can replicate.
Design specific CEO launch team touchpoints: a launch team kickoff address that sets the cultural tone for the launch journey, a midpoint message when the team is deep in the hard work of pre-launch preparation, and a launch day celebration that recognizes the team’s contribution. These are communications moments, not management moments.
The CEO who appears at the launch team’s national training meeting to deliver a 20-minute address about the product’s importance to patients, the company’s mission, and the team’s critical role creates organizational energy that sustains the team through the long months of preparation. The CEO who then disappears back into strategic work, trusting the CCO and LSC to manage the launch execution, has provided exactly the right form of leadership.
For a broader view of how launch team delegation connects to the overall pharma commercial strategy, see pharma CEO delegation guide, which provides a comprehensive framework for pharma CEO delegation across all commercial and development functions.
Handling Launch Team Escalations
Despite the best-designed delegation structure, launch teams will escalate issues to the CEO. The CEO’s handling of these escalations significantly influences whether the team continues to escalate appropriately (when genuinely needed) or over-escalates (because they learn the CEO will engage with anything that comes to them).
When a launch team escalation arrives, the CEO should ask two questions before engaging:
First: Has this been through the LSC? If not, redirect it to the LSC. The LSC is the first escalation point, not the CEO.
Second: Is this genuinely a CEO-level decision, or is it a decision the CCO or LSC should be making? If the latter, ask the CCO to make the decision and report back.
When an escalation is genuinely CEO-level, make a clear decision quickly and communicate it clearly. Launch teams that bring the CEO a genuine decision point and get a clear answer build confidence in the CEO’s engagement model. Launch teams that bring a genuine decision point and get ambiguity or redirection without resolution lose confidence in the escalation process.
Cross-Functional Conflict Resolution
Launch teams inevitably experience cross-functional conflicts. Commercial wants to move faster than regulatory is comfortable with. Supply chain wants more inventory than finance will approve. Medical Affairs and Commercial have different views on the priority KOL targets. These are not failures; they are the predictable tensions of a complex cross-functional process.
Most of these conflicts should be resolved by the LSC. The CCO’s role as LSC chair includes facilitating these cross-functional discussions to resolution. The CEO’s conflict resolution role is limited to issues where the LSC cannot reach resolution, where the conflict involves values or compliance questions that transcend commercial judgment, or where the resolution requires a resource commitment beyond the LSC’s authority.
The CEO who becomes the routine conflict resolution mechanism for launch team disagreements is undermining the LSC’s authority and creating dependence on executive resolution for decisions that functional leaders should own.
According to Harvard Business Review research on cross-functional team effectiveness, the most common failure in cross-functional teams is ambiguous authority. The launch team structure and decision rights framework above directly address this failure mode.
After the Launch: Sustaining the Team Delegation Model
The cross-functional coordination mechanisms built for a product launch represent valuable organizational infrastructure that should not be dismantled after the launch. The LSC, in modified form, becomes the ongoing commercial steering committee for the launched product. The working groups become the functional execution teams for the commercial lifecycle.
Transitioning from launch mode to commercial operations mode is itself a CEO delegation decision: when does the LSC frequency reduce, who assumes the ongoing commercial coordination responsibility, and how does the launch PMO evolve into a commercial operations support function?
These decisions should be made in advance, not improvised when the launch energy fades. Including the post-launch transition plan in the original launch governance design is a mark of strategic foresight that distinguishes excellent pharma launch leadership.
For guidance on how supply chain delegation continues to support the commercial team after launch, see pharma supply chain, which covers how pharma CEOs can maintain supply chain oversight across the full product commercial lifecycle.
The pharma CEO who builds an effective launch team delegation model does not just execute one successful launch. They build the organizational capability for launch excellence that scales across the product portfolio, creating a compounding competitive advantage through disciplined cross-functional delegation and strategic CEO leadership.
Related Reading
For further context, explore Pharma CEO Delegation for Drug Pipeline Management and Pharma CEO Delegation for Pharmacovigilance Operations.